Indivina

Medroxyprogesterone acetate, the active ingredient in Indivina, is a combined estrogen‑progestogen presented as an oral tablet for oral use. It is used to prevent pregnancy in women of reproductive age.

GNH USA supplies Indivina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indivina, a combined estrogen‑progestogen contraceptive, is used to prevent pregnancy and manage hormone‑related menstrual conditions.

- Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age. - Menstrual cycle regulation: helps achieve more regular bleeding patterns. - Treatment of dysmenorrhea: reduces painful menstrual cramps associated with ovulatory cycles.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: increased sensitivity or swelling. - Headache: occasional tension‑type headaches. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein clot formation. - Arterial thrombosis: risk of heart attack or stroke. - Hypertension: new or worsening high blood pressure. - Liver dysfunction: abnormal liver enzymes or jaundice. - Gallbladder disease: formation of gallstones. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Indivina, clinicians should consider several safety factors. - Assess thrombotic risk: evaluate personal or family history of clotting disorders. - Screen for hypertension: monitor blood pressure prior to initiation. - Review smoking status: avoid use in women over 35 who smoke. - Check liver function: contraindicated in severe hepatic disease. - Consider breast cancer history: avoid in active or recent breast cancer. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Indivina may interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may increase clotting risk. - Antiretrovirals (e.g., efavirenz): may lower hormone levels and effectiveness.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole): may raise hormone concentrations. - SSRIs (e.g., fluoxetine): may increase bleeding tendency. - Diuretics (e.g., hydrochlorothiazide): may affect electrolyte balance.